ArticleTranslational cancer research2026
Causal relationship between metabolic syndrome and gastric cancer: insights from comprehensive analysis and biomarker identification.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic syndrome (MetS) is characterized by a cluster of metabolic abnormalities, including obesity, insulin resistance, dyslipidemia, and hypertension. Increasing epidemiological evidence suggests a potential association between MetS and gastric cancer (GC); however, whether this association is causal and the underlying molecular mechanisms remain unclear. This study aimed to investigate the causal relationship between MetS and GC, and to identify potential molecular biomarkers. Methods: Mendelian randomization (MR) was applied to assess the causal effect of genetic susceptibility to MetS on GC risk. Differentially expressed genes (DEGs) were identified, followed by weighted gene co-expression network analysis (WGCNA) and protein-protein interaction (PPI) network construction to screen hub genes. To enhance the robustness of complex transcriptomic data, 113 combinations of machine learning (ML) algorithms were systematically evaluated, and the optimal model was selected to extract feature genes, assess their expression levels and diagnostic performance, and further explore potential biological functions and signaling mechanisms. Single-cell RNA sequencing (scRNA-seq) and immune cell infiltration analyses were used to evaluate the cellular distribution and immune relevance of the feature genes. Results: MR analysis revealed that genetic susceptibility to MetS increased the risk of GC (odds ratio: 1.62, 95% confidence interval: 1.12-2.33, P=0.01). A total of 1,712 DEGs and 1,314 module genes were identified, yielding 72 intersecting genes, from which the top 15 hub genes were screened. The Stepglm[backward] + XGBoost model achieved the best performance with an average area under the curve (AUC) of 0.93. Ultimately, four feature genes- Conclusions: These findings may facilitate risk stratification and early diagnosis in populations at high risk for MetS-associated GC, and provide a foundation for targeted prevention and mechanistic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.